Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
- PMID: 31299229
- DOI: 10.1016/j.neuropharm.2019.107704
Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
Abstract
Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic disorders but are ineffective for some patients and associated with side-effects and nonadherence in others. We review the in vitro, pre-clinical, clinical and molecular imaging evidence on the mode of action of antipsychotics and their side-effects. This identifies the key role of striatal dopamine D2 receptor blockade for clinical response, but also for endocrine and motor side-effects, indicating a therapeutic window for D2 blockade. We consider how partial D2/3 receptor agonists fit within this framework, and the role of off-target effects of antipsychotics, particularly at serotonergic, histaminergic, cholinergic, and adrenergic receptors for efficacy and side-effects such as weight gain, sedation and dysphoria. We review the neurobiology of schizophrenia relevant to the mode of action of antipsychotics, and for the identification of new treatment targets. This shows elevated striatal dopamine synthesis and release capacity in dorsal regions of the striatum underlies the positive symptoms of psychosis and suggests reduced dopamine release in cortical regions contributes to cognitive and negative symptoms. Current drugs act downstream of the major dopamine abnormalities in schizophrenia, and potentially worsen cortical dopamine function. We consider new approaches including targeting dopamine synthesis and storage, autoreceptors, and trace amine receptors, and the cannabinoid, muscarinic, GABAergic and glutamatergic regulation of dopamine neurons, as well as post-synaptic modulation through phosphodiesterase inhibitors. Finally, we consider treatments for cognitive and negative symptoms such dopamine agonists, nicotinic agents and AMPA modulators before discussing immunological approaches which may be disease modifying. This article is part of the issue entitled 'Special Issue on Antipsychotics'.
Keywords: Antipsychotics; Efficacy; Mechanisms; Psychosis; Schizophrenia; Side-effects; Treatment.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.CNS Drugs. 2006;20(5):389-409. doi: 10.2165/00023210-200620050-00004. CNS Drugs. 2006. PMID: 16696579 Review.
-
Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.Neuropsychopharmacology. 2007 Jun;32(6):1209-15. doi: 10.1038/sj.npp.1301242. Epub 2006 Nov 1. Neuropsychopharmacology. 2007. PMID: 17077809 Clinical Trial.
-
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.Curr Pharm Des. 2009;15(22):2550-9. doi: 10.2174/138161209788957528. Curr Pharm Des. 2009. PMID: 19689327 Free PMC article. Review.
-
Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.Jpn J Pharmacol. 2001 Aug;86(4):376-80. doi: 10.1254/jjp.86.376. Jpn J Pharmacol. 2001. PMID: 11569610 Review.
-
Atypical antipsychotics: mechanism of action.Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
Cited by
-
Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions.World Psychiatry. 2024 Feb;23(1):26-51. doi: 10.1002/wps.21159. World Psychiatry. 2024. PMID: 38214624 Free PMC article.
-
Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D2 3,4-dihydroquinolin-2(1H)-one Derivatives Related to Aripiprazole.Biomolecules. 2021 Aug 24;11(9):1262. doi: 10.3390/biom11091262. Biomolecules. 2021. PMID: 34572475 Free PMC article.
-
Two Neuroanatomical Signatures in Schizophrenia: Expression Strengths Over the First 2 Years of Treatment and Their Relationships to Neurodevelopmental Compromise and Antipsychotic Treatment.Schizophr Bull. 2023 Jul 4;49(4):1067-1077. doi: 10.1093/schbul/sbad040. Schizophr Bull. 2023. PMID: 37043772 Free PMC article.
-
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.Schizophr Bull. 2024 Jan 1;50(1):5-8. doi: 10.1093/schbul/sbad112. Schizophr Bull. 2024. PMID: 37625022 Free PMC article. No abstract available.
-
History of the dopamine hypothesis of antipsychotic action.World J Psychiatry. 2021 Jul 19;11(7):355-364. doi: 10.5498/wjp.v11.i7.355. eCollection 2021 Jul 19. World J Psychiatry. 2021. PMID: 34327128 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical